To enhance physical function of intermediate-frequency treatment instrument, separate treatment and pain threshold, and overcome adaptability to body, we analyzed FNS&SCS (fastigial nucleus stimulation and spinal cord stimulation) modules, and designed a kind of intermediate-frequency exponential pulse stimulation wave with amplitude modulated by random signal based on spectrum analysis and autocorrelation analysis. This wave can separate treatment and pain thresholds, and overcome the adaptability to body effectively.

Pancreatic cancer is one of the most common gastrointestinal malignancies,and the main unsolved obstacles,which we must figure out,are the early detection and diagnosis,and the improvement in treatments.The ceRNA (competing endogenous RNA,ceRNA) hypothesis provides significant clues and a novel direction for understanding the mechanisms of tumor occurrence and progression,microRNAs and lncRNAs (long non coding RNAs,lncRNAs) are important components in ceRNA hypothesis.Researches have discovered that both overexpression and silence of miRNAs and abnormal expression of some lncRNAs are related to the occurrence and progression of pancreatic cancer.This paper reviewed the contents and mechanisms of ceRNA hypothesis,members of ceRNA network as well as the role of ceRNAs in pancreatic neoplasms.

ObjectiveTo investigate the therapeutic effect and the mechanism of photodynamic therapy (PDT) on human pancreatic cancer xenograft in nude mice.MethodsThe animal model of human pancreatic cancer was produced by injecting human pancreatic cancer cells SW1990 into the dorsum of nude mice. After photosensitizer hematoporphyrin derivatives(HpD) was injected, the 632.8?nm He Ne laser was used to irradiate the tumor. The tumor′s volume was measured and factor Ⅷ was used for the immunohistochemical staining of the vessel change.ResultsThe tumor growth rate significantly decreased after PDT. Immunohistochemical staining showed significant vessel endothelial cell injury by PDT.ConclusionsPDT has a therapeutic effect on grafted pancreatic cancer possibly by incurring vascular injury.

Gemcitabine has become a first-line chemotherapeutic durg.Unfortunately,many patients fail to derive benefits from gemcitabine in clinics.The variability of human equilibrative nucleoside transporter 1 (hENT1)expression in tumor cells,which plays a dominant role in the transport of gemcitabine across the cell membrane,may be one of the reason for gemcitabine chemoresistance in pancreatic cancer.

Pancreatic cancer is a highly malignant tumor,the incidence is increasing year by year globally.Due to concealed pathogenesis of which and rapid progress,only 25％ of the patients could receive operation.Adjuvant therapy has become the important methods of improving the prognosis of patients with pancreatic cancer,including chemotherapy and radiotherapy.In recent years,some prospective clinical trials have promoted the development of the adjuvant therapy.New controversy and consensus appear in the treatment of pancreatic cancer.This article reviewed the progress of chemotherapy and radiotherapy for pancreatic cancer based on adjuvant therapy and neo-adjuvant therapy for unresectable metastatic pancreatic cancer and locally advanced pancreatic cancer.

Pancreatic cancer is an aggressive malignant gastrointestinal tumor,surgical resection offers the only chance of cure. Due to its anatomic and biological characters,early stage pancreatic cancer is usually clinically silent,80％-85％ of patients present with advanced unresectable disease. Furthermore,pancreatic cancer responds poorly to most radiochemotherapeutic agents.In this article,we discuss some clinical aspects including early diagnosis,preoperative systemic assessment,surgery and perioperartive adjuvant therapy,and we hope to find the challenges as well as strategies for pancreatic cancer in order to further improve the current level of diagnosis and treatment in China.

The special anatomy around the head of pancreas leads to difficulties in arriving at a definitive diagnosis for a pancreatic head mass,the management of which has recently become a hot topic and a challenge for clinicians.Despite recent advances in tumor markers,ultrasound,CT,PET/CT and MRI,some of these pancreatic head masses cannot be diagnosed with certainty.A fine needle aspiration biopsy can be used before operation; however,false negative results not infrequently happen.Based on the reports from domestic and foreign medical literatures published recently,this paper reviewed and discussed the proper treatment strategies when biopsy results from a pancreatic head mass turn out negative.

Pancreatic cancer is one of the most aggressive malignancies in the world.Little progress has been made on the treatment of advanced pancreatic cancer in the past 20 years.miRNAs perform a regulatory role in the determination of the final phenotype of cancer cells,including carcinogenesis,metastatic potential,and chemosensitivity.These features of miRNAs have turned them into one of the most popular and promising fields of scientific and clinical research.Issues such as miRNA toxicity to non-target tissues or cells and lack of proper delivery systems for human pancreatic cancer will be the challenges for the field to overcome.

Pancreatic neuroendocrine tumors(pNETs)have a low prevalence,and may be func-tional as secreting biologically active substance or nonfunctional. With the increased understanding of this disease,new technologies are being developed for diagnosis and treatment. However,surgical excision re-mains the primary therapy for localized tumors and the cure rate is not ideal yet. In choosing the appropri-ate therapy for locally advanced/ metastatic pNETs,medical management strategy should be made in a multidisciplinary context. In addition to chemotherapy,there have been significant advances in targeted mo-lecular therapy.

Drug resistance is major obstacles in the successful treatment of malignant solid tumors. Multiple mechanisms involeve in development of cancer drug resistance. Recent research suggests dysregulation of microRNAs is associated with cancer drug resistance. The profiles of microRNAs in drug resistance cancer cells or tissues are different with sensitivity cells or tissues in various solid tumors. Restoring microRNAs could improve chemosensitivity of cancer cells. MicroRNAs expression profiles may provide a critical link for understanding mechanisms involved in chemoresistance. We can also find a specific marker for screening chemosensitivity patients through identification of the microRNAs patterns of drug resistance cells or tissues.